<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02485925</url>
  </required_header>
  <id_info>
    <org_study_id>BW-201501</org_study_id>
    <nct_id>NCT02485925</nct_id>
  </id_info>
  <brief_title>SMART China, A Multi-center Clinical Registry Study</brief_title>
  <official_title>The Effectiveness and Safety in the Treatment of Circumferential Pulmonary Vein Isolation (CPVI) for Symptomatic Paroxysmal Atrial Fibrillation With THERMOCOOL® SMARTTOUCH™ Catheter in China, A Multi-center Clinical Registry Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biosense Webster, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biosense Webster, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective effectiveness and safety assessment of the study device during
      radiofrequency (RF) ablation treatment of patients with drug refractory symptomatic atrial
      fibrillation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to assess the effectiveness and safety of the THERMOCOOL®
      SMARTTOUCH™ catheter in the treatment of drug refractory symptomatic paroxysmal atrial
      fibrillation (PAF) undergoing CPVI.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2015</start_date>
  <completion_date type="Actual">June 30, 2017</completion_date>
  <primary_completion_date type="Actual">June 30, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from Documented Symptomatic Atrial Fibrillation (AF), Atrial Tachycardia (AT), or Atrial Flutter (AFL) Episodes</measure>
    <time_frame>12 month</time_frame>
    <description>The primary effectiveness endpoint for this study is freedom from documented symptomatic atrial fibrillation (AF), atrial tachycardia (AT), or atrial flutter (AFL) episodes through 12-month follow-up after the index ablation procedure (includes a three-month blanking period).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Success</measure>
    <time_frame>0.5 hour</time_frame>
    <description>Confirmation of entrance block in all pulmonary veins (PVs) with an isoproterenol intravenous challenge 0.5h post procedure. Exit Block is optional for this study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contact Force (CF)</measure>
    <time_frame>3, 6, 9 and 12 point position</time_frame>
    <description>CF and Force Time Integral (FTI) for index procedure by PV segments (from PV to the atrium, divided into 3, 6, 9 and 12 point position).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Force Time Integral (FTI)</measure>
    <time_frame>3, 6, 9 and 12 point position</time_frame>
    <description>CF and Force Time Integral (FTI) for index procedure by PV segments (from PV to the atrium, divided into 3, 6, 9 and 12 point position).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of PV Reconnection</measure>
    <time_frame>3, 6, 9 and 12 point position</time_frame>
    <description>Number, percentage and sites of PV reconnection for the index procedure (from PV to the atrium, divided into 3, 6, 9 and 12 point position).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of PV Reconnection</measure>
    <time_frame>3, 6, 9 and 12 point position</time_frame>
    <description>Number, percentage and sites of PV reconnection for the index procedure (from PV to the atrium, divided into 3, 6, 9 and 12 point position).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sites of PV Reconnection</measure>
    <time_frame>3, 6, 9 and 12 point position</time_frame>
    <description>Number, percentage and sites of PV reconnection for the index procedure (from PV to the atrium, divided into 3, 6, 9 and 12 point position).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Procedure Time</measure>
    <time_frame>Procedure</time_frame>
    <description>Total procedural, ablation (RF) time and fluoroscopy time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ablation (RF) Time</measure>
    <time_frame>Procedure</time_frame>
    <description>Total procedural, ablation (RF) time and fluoroscopy time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluoroscopy Time</measure>
    <time_frame>Procedure</time_frame>
    <description>Total procedural, ablation (RF) time and fluoroscopy time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>12 months</time_frame>
    <description>The incidence of AEs related with the procedure and study catheter</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>THERMOCOOL® SMARTTOUCH™</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>THERMOCOOL® SMARTTOUCH™</intervention_name>
    <description>Pulmonary vein isolation by RF ablation treatment with the THERMOCOOL® SMARTTOUCH™ contact force sensing catheters (study device)</description>
    <arm_group_label>Treatment group</arm_group_label>
    <other_name>Pulmonary vein isolation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 years or older

          2. Failure of at least one antiarrhythmic drug (AAD) for AF (class I or III, or AV nodal
             blocking agents such as beta blockers and calcium channel blockers) as evidenced by
             recurrent symptomatic AF, or intolerance to the AAD

          3. Patients with paroxysmal AF eligible for catheter ablation

          4. Patients with symptomatic PAF who have had at least one documented AF episode in the
             six (6) months prior to enrollment. Documentation may include but is not limited to
             electrocardiogram (ECG), Holter monitor (HM) or transtelephonic monitor (TTM)

          5. Able and willing to comply with all pre-, post- and follow-up testing and requirements

          6. Be able to sign IRB/EC-approved informed consent form

        Exclusion Criteria:

          1. AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac
             cause

          2. Previous surgical or catheter ablation for AF

          3. Any PCI, cardiac surgery, or valvular cardiac surgical or percutaneous procedure
             (e.g., ventriculotomy, atriotomy, and valve repart or replacement and presence of a
             prosthetic valve) within the past 2 months.

          4. Any carotid stenting or endarterectomy.

          5. Coronary artery bypass graft (CABG) procedure within the last 180 days (6 months)

          6. AF episodes lasting longer than 7 days or terminated via cardioversion

          7. Documented left atrial thrombus on imaging

          8. Uncontrolled heart Failure or New York Heart Association (NYHA) class III or IV

          9. Myocardial Infarction within the previous 60 days (2 months)

         10. Documented thromboembolic event (including TIA) within the past 12 months

         11. Rheumatic heart disease

         12. Awaiting cardiac transplantation or other cardiac surgery within the next 365 days (12
             months)

         13. Significant pulmonary disease, (e.g., restrictive pulmonary disease, constrictive or
             chronic obstructive pulmonary disease) or any other disease or malfunction of the
             lungs or respiratory system that produces chronic symptoms.

         14. Significant congenital anomaly or medical problem that in the opinion of the
             investigator would preclude enrollment in this study

         15. Active illness or active systemic infection or sepsis

         16. Diagnosed atrial myxoma

         17. Unstable angina within the past 60 days (2 months)

         18. History of blood clotting or bleeding abnormalities

         19. Life expectancy less than 365 days (12 months)

         20. Hypertrophic obstructive cardiomyopathy

         21. Presence of implanted ICD

         22. Contraindication to anticoagulation

         23. Contraindication to isoproterenol

         24. Presence of intramural thrombus, tumor or other abnormality that precludes catheter
             introduction or manipulation

         25. Women who are pregnant and/or breast feeding

         26. Presence of a condition that precludes vascular access.

         27. Patients presenting contraindications for study catheter(s), as indicated in the
             respective Instructions For Use

         28. Enrollment in an investigational study evaluating another device, biologic, or drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Congxin Huang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Renmin Hospital of Wuhan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Chao-Yang Hospital</name>
      <address>
        <city>Chaoyang</city>
        <state>Beijing</state>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fu Wai Hospital CAMS&amp;PUMC</name>
      <address>
        <city>Xicheng</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renmin Hospital of Wuhan University</name>
      <address>
        <city>Wuchang</city>
        <state>Hubei</state>
        <zip>430060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wu Han Asia Heart Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xuzhou Central Hospital</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <zip>221009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital to Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <zip>116011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The General Hospital of Shenyang Military Region</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110015</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qi Lu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Affiliated to Tianjin Medical University</name>
      <address>
        <city>Heping</city>
        <state>Tianjin</state>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://www.biosensewebster.com/WorldWide/</url>
    <description>Sponsor website</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2015</study_first_submitted>
  <study_first_submitted_qc>June 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2015</study_first_posted>
  <last_update_submitted>July 21, 2017</last_update_submitted>
  <last_update_submitted_qc>July 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Interventional</keyword>
  <keyword>Radiofrequency ablation</keyword>
  <keyword>Paroxysmal Atrial Fibrillation</keyword>
  <keyword>Catheter ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

